Skip to content
value.today

Zero Point Five Therapeutics, Inc.

🇺🇸 Baltimore, Maryland, USABiotechnologyFounded 2018
Total raised
$12 M
2 rounds on record
Latest round
$4 M
Apr 2025
First round on record
Jun 2023
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Zero Point Five Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2025$4 MNo. 2$2 to $10 million

Zero Point Five Therapeutics, Inc.: Raise no. 2, Apr 2025

Investors in this round

10 investors had bought by the notice of Apr 17, 2025: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in District Of Columbia

People named in the notice

  • Joseph Amprey III · Executive Officer, Director
  • Ben Auspitz · Director
  • Jodi Jahic · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph Amprey III, Ceo. Source: SEC Form D, newest notice filed Apr 17, 2025. Read the notice at the SEC.

equitySEC
Jun 2023$7 MNo. 1$2 to $10 million

Zero Point Five Therapeutics, Inc.: Raise no. 1, Jun 2023

Investors in this round

15 investors had bought by the notice of Jul 12, 2023: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $10 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joseph Amprey III · Executive Officer, Director
  • Ben Auspitz · Director
  • Jodi Jahic · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joseph Amprey III, Ceo. Source: SEC Form D, newest notice filed Jul 12, 2023. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Zero Point Five Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2025).

    SEC Form D · Apr 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Apr 2025

That is all the official record says: Zero Point Five Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Zero Point Five Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 15 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Zero Point Five Therapeutics, Inc.
NameRoleNamed in
Joseph Amprey IIIExecutive officerApr 2025
Ben AuspitzDirectorApr 2025
Jodi JahicDirectorApr 2025
Joseph Amprey IIIDirectorApr 2025